Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 2/20 | 0.52 |
| ▸ | ADK | P55263 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900475 | 0.87 | GRK6 (0.56) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4901149 | 0.82 | ADK (0.56) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4875694 | 0.76 | GRK6 (0.59) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL12870524 | 0.75 | ADK (0.64) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4866861 | 0.75 | ADK (0.64) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4864853 | 0.73 | ADK (0.77) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4874835 | 0.73 | GRK6 (0.61) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4873338 | 0.73 | ADK (0.57) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL4870544 | 0.71 | ADK (0.53) | GRK6ADKCA1CA2TSHR | |
| SCHEMBL14353020 | 0.71 | GRK6 (0.69) | GRK6ADKCA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | GRK6 3946/4885ADK 523/4885CA1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.